

## Patients Withdrawing Dupilumab Monotherapy for COVID-19–Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

To the Editor:

Atopic dermatitis (AD) is a chronic inflammatory skin disease that is treated with phototherapy or systemic therapies when the disease is assessed as moderate-severe and unresponsive to topical therapies.

During COVID-19 pandemic, a few studies described the therapeutic management of AD.<sup>1–3</sup> In Italy, the DA-COVID-19 national registry was created to collect clinical data about the management of moderate-severe AD patients during the lockdown period (starting from February to June 2020). Pandemic-related sanitary restrictions limited the access to hospitals and determined the implementation of regular visits with telemedicine, resulting in a predominant patient-oriented assessment of disease severity.<sup>3</sup> Three time points for data collection were considered.<sup>3</sup>

Herein,<sup>3</sup> we describe AD course after dupilumab withdrawal. The effectiveness of dupilumab in the treatment of moderate-severe AD has been widely characterized in both real-world and clinical trial settings.<sup>4,5</sup> However, there is no evidence about the maintenance of treatment response after withdrawal of dupilumab therapy.

*DA-COVID-19 Study Group: Dario Francesco D'Urso, Dionisio Silvaggio, Annunziata Dattola, Maddalena Napolitano, Giacomo Dal Bello, Tommaso Bianchelli, Chiara Rovati, Flavia Pigliacelli, Michela Ortoncelli, Katharina Hansel, Alvise Sernicola, Giulia Calabrese, Camilla Loi, Michela Iannone, Federica Veronese, Filomena Russo, Paolo Romita, Greta Tronconi, Francesca Caroppo, Giovanna Tilotta, Maria Esposito, Francesca Raponi, Giulio Gualdi, Giulia Rech, Maria Letizia Musumeci, Steven Paul Nisticò, Alessio Campitiello, Laura Bonzano, Viviana Piras*

A.C., L.DN., M.T., and M.G. contributed equally to this work.

A.C. served as advisory board member and consultant receiving fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Fresenius Kabi, Leo Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB Pharma. G.F. acted as speaker and consultant for AbbVie and Leo Pharma. G.G. has been principal investigator in clinical trials sponsored by and/or has received personal fees from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol-Meyers Squibb, Celgene, Eli Lilly, Leo Pharma, Novartis, OM Pharma, Pfizer, Regeneron, Samsung, and Sandoz. A.O. has been a scientific consultant/speaker/clinical study investigator for AbbVie, Celgene, Janssen, Leo Pharma, Eli Lilly, MSD, Novartis, Pfizer, Sanofi, Alfasigma, and Almirall. M.T.R. has received personal fee for advisory board meeting from Sanofi, AbbVie, Novartis, and Cantabria. L.B. reports personal fees from speaker and as consultant for AbbVie, Novartis, Janssen-Cilag, Pfizer, UCB, and Leo Pharma, outside the submitted work. L.S. has been principal investigator in clinical trials sponsored by and/or received personal fees from AbbVie, Almirall, Celgene, Eli Lilly, Janssen, Novartis, and Sanofi-Genzyme. G.P. has been principal investigator in clinical trials sponsored by and/or received

Of 1013 patients treated with dupilumab monotherapy, 75 (7.4%) interrupted therapy, with a mean duration of treatment withdrawal of 106.4 days ( $\pm 75.83$  days). Significant differences between the subgroup of patients continuing and patients withdrawing therapy throughout the study period were detected, highlighting a lower degree of disease severity in patients continuing therapy (data not shown). In particular, patient self-reported AD severity status showed significantly higher scores in patients withdrawing treatment, independent of the cause of interruption, at any time point (Table 1). Thirty-six of 75 patients withdrew therapy because of the risk factors related to COVID-19 disease (age >65 years, metabolic and/or cardiovascular comorbidities), SARS-CoV-2 infection, fear of increased susceptibility to SARS-CoV-2 infection, or close contact with SARS-CoV-2+ subjects.

Changes in mean scores for Eczema Area and Severity Index (EASI), Itch–Numeric Rating Scale (Itch-NRS), and Sleep–Numeric Rating Scale (Sleep-NRS) from time point 3 and time point 1 were not significantly different in the subcohort of patients withdrawing because of SARS-CoV-2–related reasons versus patients continuing dupilumab therapy (Table 1). In this subcohort of patients, mean dupilumab withdrawal period resulted longer intervals ( $123.2 \pm 11.69$  days) compared with patients discontinuing dupilumab because of reasons unrelated to SARS-CoV-2 infection ( $90.03 \pm 12.91$  days), although this difference was not statistically significant ( $P = 0.0615$ ).

*personal fees from AbbVie, Almirall, Eli Lilly, Leo Pharma, Novartis, and Sanofi. A.P. has served as a speaker and received honoraria from Sanofi-Genzyme for lectures, research grants, and as an advisory board member. C.F. has been speaker for Sanofi and AbbVie. M.C.F. has served on advisory boards, received honoraria for lectures, and research grants from Almirall, AbbVie, Galderma, Leo Pharma, Mylan, Medac Pharma, Celgene, Pierre Fabre, UCB, Eli Lilly, Pfizer, Janssen, Novartis, Sanofi Genzyme, Roche, Sun Pharma, and MSD. F.R. has served on advisory board, received honoraria for lectures and research grants from Novartis, AbbVie, Janssen-Cilag, Eli Lilly, Leo Pharma, and Sanofi-Genzyme. P.A. has received speaker honoraria from Sanofi, AbbVie, Janssen, Celgene, Novartis, and Sandoz. G.M. has been a scientific consultant/clinical study investigator for AbbVie, Eli Lilly, Janssen-Cilag, Leo Pharma, and Novartis. C.P. has been a consultant and held sponsored conferences for AbbVie, Novartis, Pfizer, and Sanofi. I.Z. has been a consultant and/or speaker for Novartis, Celgene, and Amgen. K.P. reports grants and personal fees for advisory board meeting from Almirall, AbbVie, Biogen, Lilly, Celgene, Galderma, Leo Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz, Sun Pharma, and Janssen. S.F. has been principal investigator in clinical trials by AbbVie and Sanofi-Genzyme, has served on advisory board, received honoraria for lectures and research grants from Novartis, Menarini, and Almirall. The remaining authors have no funding or conflicts of interest to declare.*

*IRB approval status: Approved by the national ethical committee for COVID-19–related studies (Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani I.R.C.C.S.).*

DOI: 10.1097/DER.0000000000000814

© 2021 American Contact Dermatitis Society. All Rights Reserved.

**TABLE 1. AD Course in Patients Withdrawing Dupilumab Monotherapy Because of Reasons Related or Unrelated to SARS-CoV-2 Infection**

|   |   | Patients<br>Continuing<br>Dupilumab<br>Monotherapy | Patients<br>Withdrawing<br>Dupilumab<br>Monotherapy for<br>SARS-CoV-2+ | <i>P</i> for Comparison<br>Patients<br>Continuing vs<br>SARS-CoV-2–<br>Related<br>Withdrawing | Patients<br>Withdrawing<br>Dupilumab<br>Monotherapy for<br>Unrelated SARS-<br>CoV2 Causes | <i>P</i> for Comparison<br>Patients<br>Continuing vs<br>SARS-CoV-2–<br>Unrelated<br>Withdrawing |
|---|---|--|--|---|---|---|
| No. patients undergoing dupilumab monotherapy,<br>N = 1013    |   | n = 938  | n = 36   |   | n = 39  |   |
| Time point 1 (initial<br>phase of lockdown)                   | Mean EASI score (±SD)   | 5.6 (7.2)  | 6.0 (7.0)  | 0.7122  | 8.0 (8.7)   | 0.044   |
|   | Mean Itch-NRS score (±SD)   | 2.0 (1.9)  | 3.0 (2.1)  | 0.0015  | 3.4 (2.4)   | <0.0001   |
|   | Mean Sleep-NRS score<br>(±SD)                                     | 1.3 (1.7)  | 2.2 (2.3)  | 0.0007  | 2.3 (2.6)   | 0.0002  |
|   | AD-NRS score (±SD)  | 1.9 (1.8)  | 2.7 (2.1)  | 0.0197  | 3.1 (2.4)   | 0.003   |
|   | Self-reported Improved<br>AD status no. pts (%)                   | 262 (28.0)   | 7 (19.4)   | 0.0002  | 7 (17.9)  | <0.0001   |
|   | Stable no.<br>pts (%)   | 612 (65.4)   | 20 (55.6)  |   | 17 (43.6)   |   |
|   | Worsened no.<br>pts (%)   | 62 (6.6)   | 9 (25.0)   |   | 15 (38.5)   |   |
|   | Mean Itch-NRS score (±SD)   | 1.7 (1.8)  | 2.8 (2.6)  | 0.0307  | 3.8 (2.8)   | <0.0001   |
|   | Mean Sleep-NRS score<br>(±SD)                                     | 1.1 (1.5)  | 2.4 (2.6)  | 0.0096  | 2.3 (2.8)   | 0.04  |
| Time point 2 (visit in<br>remote modality<br>during lockdown) | AD-NRS score (±SD)  | 1.7 (1.7)  | 2.9 (2.8)  | 0.042   | 3.0 (2.6)   | 0.006   |
|   | Improved<br>no. pts (%)   | 262 (28.5)   | 7 (21.2)   |   | 10 (27.8)   |   |
|   | Self-reported Stable no.<br>AD status pts (%)                     | 601 (65.4)   | 14 (42.4)  | <0.0001   | 16 (44.4)   | <0.0001   |
|   | Worsened n.<br>pts (%)  | 56 (6.1)   | 12 (36.4)  |   | 10 (27.8)   |   |
| Time point 3 (latest<br>phase of lockdown)                    | Mean EASI score (±SD)   | 5.8 (15.1)   | 5.3 (6.7)  | 0.91  | 12.3 (10.0)   | 0.064   |
|   | Mean Itch-NRS score (±SD)   | 1.6 (1.7)  | 2.9 (3.0)  | <0.0001   | 3.7 (3.0)   | <0.0001   |
|   | Mean Sleep-NRS score<br>(±SD)                                     | 0.9 (1.4)  | 2.0 (2.5)  | <0.0001   | 2.6 (2.9)   | <0.0001   |
|   | AD-NRS score (±SD)  | 1.6 (1.7)  | 2.5 (2.6)  | 0.074   | 3.2 (2.8)   | 0.0006  |
|   | Self-reported Improved no.<br>AD status pts (%)                   | 258 (28.9)   | 7 (20.0)   | <0.0001   | 11 (33.3)   | 0.0019  |
|   | Stable no.<br>pts (%)   | 593 (66.3)   | 17 (48.6)  |   | 16 (48.5)   |   |
|   | Worsened no.<br>pts (%)   | 43 (4.8)   | 11 (31.4)  |   | 6 (18.2)  |   |
|   | <b>Change in EASI score from time point 1 to<br/>time point 3</b> | <b>–1.6 (5.4)</b>                                  | <b>0.6 (5.6)</b>   | <b>0.147</b>  | <b>2.3 (9.4)</b>  | <b>0.003</b>  |
|   | <b>Change in Itch-NRS from time point 1 to<br/>time point 3</b>   | <b>–0.3 (1.8)</b>                                  | <b>0.1 (3.4)</b>   | <b>0.177</b>  | <b>0.4 (3.3)</b>  | <b>0.019</b>  |
|   | <b>Change in Sleep-NRS from time point 1 to<br/>time point 3</b>  | <b>–0.3 (1.6)</b>                                  | <b>–0.2 (3.0)</b>  | <b>0.758</b>  | <b>0.4 (3.2)</b>  | <b>0.013</b>  |

Data are reported as means (±SD) or numbers (%).

AD, atopic dermatitis; EASI, Eczema Area and Severity Index; NRS, Numeric Rating Scale; pts, patients; SD, standard deviation.

Of 75 patients, 39 patients withdrew dupilumab therapy because of reasons unrelated to COVID-19 disease, including ineffectiveness, adverse events, patient's decision, and issues with drug supply. In contrast to patients withdrawing therapy because of

SARS-CoV-2–related reasons, these patients experienced a significant worsening of AD with greater changes in mean EASI score, Itch-NRS, and Sleep-NRS at time point 3 versus time point 1, compared with patients continuing therapy (Table 1). Thus, this

study provides relevant insights for physicians about the management of AD patients after dupilumab suspension or withdrawal during COVID-19 pandemic, because a 16-week interruption due to SARS-CoV-2–related reasons did not cause a significant relapse or worsening of the disease.

*Andrea Chiricozzi, MD*

Dermatologia  
Dipartimento Scienze Mediche e Chirurgiche  
Fondazione Policlinico Universitario A. Gemelli IRCCS  
Rome, Italy  
Dermatologia  
Dipartimento Universitario di Medicina e Chirurgia Traslazionale  
Università Cattolica del Sacro Cuore  
Rome, Italy  
chiricozziandrea@gmail.com

*Lucia Di Nardo, PhD*

Dermatologia  
Dipartimento Universitario di Medicina e Chirurgia Traslazionale  
Università Cattolica del Sacro Cuore  
Rome, Italy

*Marina Talamonti, MD*

*Marco Galluzzo, MD*  
Dermatology Unit  
Policlinico Tor Vergata  
Department of Systems Medicine  
Tor Vergata University of Rome  
Italy

*Clara De Simone, MD*

Dermatologia  
Dipartimento Scienze Mediche e Chirurgiche  
Fondazione Policlinico Universitario A. Gemelli IRCCS  
Rome, Italy  
Dermatologia  
Dipartimento Universitario di Medicina e Chirurgia Traslazionale  
Università Cattolica del Sacro Cuore  
Rome, Italy

*Gabriella Fabbrocini, MD*

Section of Dermatology  
Department of Clinical Medicine and Surgery  
University of Naples Federico II  
Naples, Italy

*Angelo Valerio Marzano, MD*

Dermatology Unit  
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico  
Milan, Italy  
Department of Pathophysiology and Transplantation  
Università degli Studi di Milano  
Milan, Italy

*Giampiero Girolomoni, MD*

Section of Dermatology and Venereology  
Department of Medicine  
University of Verona  
Italy

*Annamaria Offidani, MD*

Dermatological Clinic  
Department of Clinical and Molecular Sciences  
Polytechnic University of the Marche Region  
Ancona, Italy

*Maria Teresa Rossi, MD*

Department of Dermatology  
ASST Spedali Civili of Brescia  
University of Brescia  
Italy

*Luca Bianchi, MD*

Dermatology Unit  
Policlinico Tor Vergata  
Department of Systems Medicine  
Tor Vergata University of Rome  
Italy

*Antonio Cristaudo, MD*

Clinical Dermatology  
San Gallicano Dermatological Institute  
Rome, Italy

*Maria Teresa Fierro, MD*

Medical Sciences Department  
Dermatologic Clinic  
University of Turin  
Italy

*Luca Stingeni, MD*

Dermatology Section  
Department of Medicine  
University of Perugia  
Italy

*Giovanni Pellacani, MD*

Unit of Dermatology  
Department of Clinical Internal  
Anesthesiological, and Cardiovascular Sciences  
Sapienza University of Rome  
Italy

*Giuseppe Argenziano, MD*

Dermatology Unit  
University of Campania Luigi Vanvitelli  
Naples, Italy

*Annalisa Patrizi, MD*

Dermatology UOC  
Department of Experimental  
Diagnostic and Specialty Medicine  
University of Bologna  
Italy

*Paolo Pigatto, MD*

Department of Biomedical  
Surgical and Dental Sciences  
Clinical Dermatology  
IRCCS Galeazzi Orthopaedic Institute  
University of Milan  
Italy

*Marco Romanelli, MD*  
 Department of Dermatology  
 University of Pisa  
 Italy

*Paola Savoia, MD*  
 Department of Health Sciences  
 Amedeo Avogadro University of Eastern Piedmont  
 Novara, Italy

*Pietro Rubegni, MD*  
 Dermatology Unit  
 Department of Medical  
 Surgical and Neurosciences  
 University of Siena  
 Italy

*Caterina Foti, MD*  
 Department of Biomedical Science and Human Oncology  
 Unit of Dermatology  
 University of Bari  
 Italy

*Nicola Milanese, MD*  
 Dermatology Clinic  
 Department of Health Sciences  
 University of Florence  
 Italy

*Anna Belloni Fortina, MD*  
 Dermatology Unit  
 Department of Medicine DIMED  
 University of Padova  
 Italy

*Maria Rita Bongiorno, MD*  
 Section of Dermatology  
 Department of Health Promotion  
 Mother and Child Care  
 Internal Medicine and Medical Specialties  
 University of Palermo  
 Italy

*Teresa Grieco, MD*  
 Unit of Dermatology  
 Department of Clinical Internal  
 Anesthesiological, and Cardiovascular Sciences  
 Sapienza University of Rome  
 Italy

*Sergio Di Nuzzo, MD*  
 Department of Medicine and Surgery  
 University of Parma  
 Italy

*Maria Concetta Fargnoli, MD*  
 Dermatology  
 Department of Biotechnological and Applied Clinical Sciences  
 University of L'Aquila  
 Italy

*Andrea Carugno, MD*  
 Dermatology Unit  
 ASST Papa Giovanni XXIII Hospital  
 Bergamo, Italy

*Alberico Motolese, MD*  
 Dermatology Unit  
 Department of Medical Specialties  
 Arcispedale Santa Maria Nuova-IRCCS di Reggio Emilia  
 Italy

*Franco Rongioletti, MD*  
 Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital  
 Milan, Italy  
 Unit of Dermatology  
 Department of Medical Sciences and Public Health  
 University of Cagliari  
 Italy

*Paolo Amerio, MD*  
 Department of Medicine and Aging Science  
 Dermatologic Clinic  
 G. D'Annunzio University  
 Chieti, Italy

*Riccardo Balestri, MD*  
 Division of Dermatology  
 Santa Chiara Hospital  
 Trento, Italy

*Concetta Potenza, MD*  
 Department of Medico-Surgical Sciences and Biotechnologies  
 Dermatology Unit 'Daniele Innocenzi' Sapienza University of  
 Rome–Polo Pontino  
 Italy

*Giuseppe Micali, MD*  
 Dermatology Clinic  
 University of Catania  
 Italy

*Cataldo Patruno, MD*  
 Dermatology Unit  
 Department of Health Sciences  
 Università Magna Graecia  
 Catanzaro, Italy

*Iris Zalaudek, MD*  
 Department of Dermatology  
 University of Trieste  
 Italy

*Maurizio Lombardo, MD*  
 Unit of Dermatological Diseases  
 ASST Sette Laghi  
 Ospedale di Circolo  
 Varese  
 Italy

*Claudio Feliciani, MD*  
 Section of Dermatology  
 Department of Medicine and Surgery

University of Parma  
Italy

Flaminia Antonelli, MD  
Dermatologia  
Dipartimento Scienze Mediche e Chirurgiche  
Fondazione Policlinico Universitario A. Gemelli IRCCS  
Rome, Italy  
Dermatologia  
Dipartimento Universitario di Medicina e Chirurgia Traslazionale  
Università Cattolica del Sacro Cuore  
Rome, Italy

Silvia Mariel Ferrucci, MD  
Dermatology Unit  
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico  
Milan, Italy

Fabrizio Guarneri, MD  
Dermatology  
Department of Clinical and Experimental Medicine  
University of Messina  
Italy

Ketty Peris, MD  
Dermatologia  
Dipartimento Scienze Mediche e Chirurgiche  
Fondazione Policlinico Universitario A. Gemelli IRCCS  
Rome, Italy  
Dermatologia  
Dipartimento Universitario di Medicina e Chirurgia Traslazionale  
Università Cattolica del Sacro Cuore  
Rome, Italy

## REFERENCES

1. Stिंगeni L, Hansel K, Antonelli E, et al. Atopic dermatitis in adolescents: effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy. *Dermatol Ther*. 2021;34:e15035. 10.1111/dth.15035. Epub ahead of print.
2. Rossi M, Rovati C, Arisi M, et al. Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: a single-center real-life experience. *Dermatol Ther* 2020;33(4):e13765.
3. Chiricozzi A, Talamonti M, De Simone C, et al, DA-COVID-19 study group. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry. *Allergy* 2021;76(6):1813–1824.
4. Gori N, Chiricozzi A, Malvaso D, et al. Successful combination of systemic agents for the treatment of atopic dermatitis resistant to dupilumab therapy. *Dermatology* 2021;237(4):535–541.
5. Deleuran M, Thaçi D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. *J Am Acad Dermatol* 2020;82(2): 377–388.

## A Case of Facial Contact Dermatitis Due to E-Cigarette Flavored Liquids

To the Editor:

E-cigarettes are devices that transform liquids into an aerosol through heating, and over the last few years, their use has skyrocketed.

Numerous vaping-associated dermatological conditions have been reported, such as thermal injuries, oral lesions, and contact dermatitis.<sup>1</sup>

We report a case of allergic contact dermatitis (ACD) related to flavorings contained in e-cigarette refill oils.

A 54-year-old nonatopic woman presented with an itchy, eczematous dermatitis of the perioral region that had started 2 months prior (Fig. 1).

The patient's medical history included systemic scleroderma, diagnosed in 1984.

Patch testing was performed with the Società Italiana di Dermatologia Allergologica Professionale e Ambientale baseline series. Patch test chambers (Van der Bend, Brielle, the Netherlands) were applied on the upper part of the patient's back.

The readings on days 2 and 3, according to the Italian guidelines,<sup>2</sup> showed positive reactions to fragrance mix I (sorbitan sesquiolate) 8% (-/+--), fragrance mix II 14% (++-/++-), hydroxyisohexyl 3-cyclohexene carboxaldehyde 5% (Lyril, +- -/++-), and *Myroxylon pereirae* 25% (-/+--).

The patient reported the use of some cosmetics and the habit of smoking with an e-cigarette refilled with flavored e-liquids.

Patch tests with the patient's products were carried out (lip balm, face cosmetic cream, surgical mask used during the pandemic) and even the vaping liquids tested as is ("biscuit scent" and "shinobi oil").

The readings were all negative.

We also tested propylene glycol 5% petrolatum, a common allergen related to vaping, which was negative.

A repeated open application test with both the e-cigarette refill oils was negative after 7 days.

The stop-restart test with the e-cigarette refill oils was strongly and repeatedly positive.

Several allergens contained in e-cigarettes can cause ACD (Table 1).

Nickel has been found to be the responsible allergen for hand dermatitis in some cases, because of the repeated contact with

---

Address reprint requests to Natale Schettini, Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Azienda Ospedaliera-Universitaria di Ferrara, Via Aldo Moro 8, 44124, Ferrara, Italy. E-mail: [natale.schettini@gmail.com](mailto:natale.schettini@gmail.com).

The authors have no funding or conflicts of interest to declare.

DOI: 10.1097/DER.0000000000000892

© 2022 American Contact Dermatitis Society. All Rights Reserved.